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All-trans retinoic acid (ATRA) was found to inhibit cell growth, induce differentiation and enhance 
apoptosis in a variety of malignant solid tumors. Retinoic acid is effective in inhibiting the expression of 
vascular endothelial growth factor (VEGF) in some cancer. In this study, we investigated the effect of 
ATRA on the expression of VEGF and its receptors in LoVo cells, and its possible mechanisms. LoVo 
cells were treated with ATRA at different concentrations for different time, and with exogenous 
recombinant human VEGF165 or VEGF165 + ATRA. Cell viability was measured by microtitration (MTT) 
assay. Cell cycle and apoptosis were evaluated by flow cytometry (FCM). The expression of VEGF in 
LoVo cells were detected by ELISA technique and Western blot, and its receptors by flow cytometry. 
ATRA greatly inhibited the proliferation of LoVo cells in dose- and time-dependent manners; inhibition 
rate of the cells decreased significantly after treatment with ATRA. ATRA could dose-dependently block 
the VEGF165-induced cell growth. FCM results show that ATRA induced apoptosis of LoVo cells with 
concomitant decrease of expressed VEGF and its receptors. The mechanism involved in down 
regulation of VEGF and its receptors may be related to apoptosis. ATRA could also disturb the 
stimulating effect of VEGF165 on the growth of LoVo cells. These results suggest that ATRA can delay 
growth of LoVo cells by inhibiting the paracrine and autocrine pathways.  
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The dependence of tumour growth and metastasis on 
blood vessels makes angiogenesis one of the 
fundamental hallmarks of cancer (Hanahan and 
Weinberg, 2000) and a rational target for (Carmeliet and 
Jain, 2000) several growth factor receptor pathways that 
have been implicated in the promotion of tumour 
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process is the vascular endothelial growth factor (VEGF) 
family of proteins, also known as vascular permeability 
factors, and its receptors. Finding a way to inhibit the 
expression of VEGF and its receptors has been of great 
interest. Recent studies have suggested that ATRA is 
effective in inhibiting the expression of VEGF in some 
cancer. However, there has been no research carried out 
on ATRA inhibition of the expression of VEGF and its 
receptors in colon cancer. Therefore, we investigated the 
effect of ATRA on the expression of VEGF and its 
receptors in LoVo cells, and its possible mechanisms in 








MATERIALS AND METHODS 
 
LoVo cells were obtained from ATCC (Rockville, MD, USA). ATRA, 
RPMI-1640, 25% parenzyme, acridine orange (AO), ethidium 
bromide (EB), dimethyl sulfoxide (DMSO) and iodine were 
purchased from Sigma Co (USA); fetal bovine serum (FBS) was 
obtained from Sijiqing, China; methyl thiazolyl tetrazolium (MTT) 
was obtained from Fluka. Human VEGF ELISA kit, VEGF165 and 
phycoerythrin-conjugated mouse monoclonal anti
1, VEGFR-2 and VEGFR-3 were obtained from R&D Co (USA). 
Flow cytometry was obtained from BD Biosciences, USA. Annexin 





LoVo cells were cultured in RPMI-1640 supplemented with 10% 
FBS. The cultures were incubated at 37°C in a humidified 5% CO
incubator. Cells were harvested at mid-log phase and the culture 





LoVo cells were inoculated into three 96-hole culture plates when 
cells were in the denary logarithmic growth condition. The cells 
were divided into a control group, a 10-5 ATRA group, 10
group, and a 10-7 mol/L ATRA group, and the cells were cultured for 
24, 48 and 72 h. MTT and DMSO were added to the cell cultures 
and the OD-value at 570 nm wavelength was measured for each  
treatment group using the MTT assay. Finally, in order to calculate 
the survival ratio of the cells, the following formula was used: 
 
 
LoVo cells were seeded in another 96-well plate. When cells were 
in the denary logarithmic growth condition, exogenous recombinant 
human VEGF165 (2.5, 5, 15 and 20 ng/ml) or VEGF
and 20 ng/ml) + 10-5 mol/L ATRA or VEGF165 (2.5, 5, 15 and 20 
ng/ml) + 10-6 mol/L ATRA or VEGF165 (2.5, 5, 15 and 20 ng/ml) + 10
7 mol/L ATRA were added to the medium in three parallel wells 
each, and cultured for a further 48 h. For control wells, an equal 
volume of medium was added. The methods for the MTT assay and 




Cell cycle assessment of LoVo cells  
 
LoVo cells were seeded in a 24-well plate (1 × 10
48 h seeding, cells were treated with ATRA (10
mol/L) for 48 h, and untreated cells served as controls. Then the 
cells were washed with phosphate buffer saline (PBS), re
suspended in 500 l of PBS and fixed in 500 l of ice
ethanol at −20°C. After incubation for 30 min, the cell pellets were 
collected by centrifugation, re-suspended in 0.5 ml of PBS 
containing 100 g/ml RNase and incubated at 37°C for 30 min. 
Then 0.5 ml of propidium iodide solution (50 g/ml in PBS) was 
added and the mixture was allowed to stain on ice for 30 min. The 







165 (2.5, 5, 15 
-
6 cells/well). After 
-7, 10-6 and 10-5 
-
-cold absolute 
 The  cell  cycle  




phase distribution was analyzed using 
 
 
Cell apotosis assessment of LoVo cells by annexin V
staining 
 
The methods for treating the LoVo cells were the same as 
aforementioned. By 48 h, the cells were washed twice with cold 
PBS and then re-suspended in a binding buf
of 1 × 106 cells/ml, and the 100 
transferred to 5 ml culture tubes. 5 µl of annexin V
propidium iodide (PI) (g/ml) were added to each 100 
and the cells were gently vortexed
room temperature in the dark. The samples, to which 400 
was added, were analyzed by FACSCalibur flow cytometer. Early 




VEGF ELISA assay 
 
LoVo cells were inoculated into three 6
cells were in the denary logarithmic growth condition. The cells 
were divided into a control group, a 10
group and a 10-7 mol/L ATRA group. After the cells were cultured for 
24, 48 and 72 h, 5 ×106 cells were transferred to 5 ml RPMI
and cultured for 48 h. Then the culture
centrifuged at 2000 r/min for 8~10 min, and stored at 
experiment was done according to the instruction of the reagent 





LoVo cells treated with different concentrations of ATRA for 72 h 
were harvested and lysed. The protein concentration was 
determined by the method of Bradford with Coomassie
using bovine serum albumin as standard. Western blotting was 
performed according to a method previously described with a 
modification. Proteins were electrophoresed on 10% SDS
polyacrylamide gels and transferred to a 
(PVDF) membrane. After pre-blocking with PBS containing 0.05% 
Tween 20 (PBS-T) and 5% non-fat milk for 30 min at normal 
temperature, the membrane was incubated with a 1:100 dilution of 
rabbit anti-VEGF serum for 1 h at normal temperature. Horseradish 
peroxidase conjugated goat anti
Biotechnology) was applied as a secondary antibody using a 1:800 
dilution. Immunoreactive bands were detected using the 3, 3
diaminobenzidine as substrate. As an internal control, the 
membrane was probed with antibeta
experiment is representative of three separate determinations.
 
 
Measurement of VEGF-Receptors 
 
LoVo cells were inoculated into three 6
cells were in the denary logarithmic growth condition. The cells
were divided into a control group, a 10
group and a 10-7 mol/L-ATRA group. After the cells were cultured for 
24, 48 and 72h, cells of each bottle were collected and centrifuged 
at 3000 r/min for 5 min and washed three times in an i
buffer (supplemented with 0.5% BSA). Cells were then re
suspended in the same buffer to a final concentration of 4 × 10
cells/ml and 25  of cells (1 ×105) were transferred to a 5 ml tube 
for staining. The following experimental procedures wer
carried out; 1) cells were Fc-blocked by treatment with 1 l of 
human I gG/105 cells for 15 min at room temperature prior to 
staining;  2)  25  L   of   the   Fc-blocked 
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transferred to a 5 ml tube; 3) 10 l of PE-conjugated anti-VEGF R1 
reagent was added; 4) Incubation was done for 30 to 45 min at 2 to 
8°C; 5) following the incubation, unreacted anti-VEGF R1 reagent 
was removed by washing the cells twice in 4 ml of the same PBS 
buffer; 6) the cells were re-suspend in 200 to 400 l of PBS buffer 
for final flow cytometric analysis; 7) as a control for analysis, cells in 
a separate tube were treated with PE-labeled mouse IgG1 antibody. 
The same procedures were done for anti-VEGF R2 or anti-VEGF 
R3 reagent and the effect was explored on the other two receptors. 





Differences in data between the groups were compared by one and 
two-way ANOVA. If the analysis was significant, then each mean 
was compared with each other mean using Student-Newman-Keul’s 
method. The frequencies of positive cells were compared using the 
Chi-square test. Statistical significance was defined as P<0.05. 





Effect of ATRA on cell growth in LoVo cells 
 
The cell proliferation was determined using the MTT 
assay performed with logarithmically growing LoVo cells 
treated with ATRA. Within 24 h of the addition of 10-7 
mol/L ATRA on the LoVo cells, the inhibition rate was 5.58 
± 0.03% (P<0.05). ATRA inhibited the growth of LoVo 
cells in time-dependent and dose-dependent inhibitory 
fashions at concentrations of 10-7~10-5 mol/L (Figure 1). 
These data imply that ATRA has a significant growth 
inhibitory effect on LoVo cells in vitro. 
LoVo cells were incubated with varying concentrations 
of VEGF165 (2.5, 5, 15 and 20 ng/ml) or VEGF165 (2.5, 
5, 15 and 20 ng/ml) + 10 to 5 mol/L ATRA or VEGF165 
(2.5, 5, 15 and 20 ng/ml) + 10 to 6 mol/L ATRA or 
VEGF165 (2.5, 5, 15 and 20 ng/ml) + 10 to 7 mol/L ATRA. 
Its effects were measured using the MTT assay (Table 1). 
The results show that VEGF165 accelerated the growth 




Effect of ATRA on cell cycle in LoVo cells  
 
The effect of ATRA on cell cycle phase distribution was 
analyzed by flow cytometer. The results showed that the 
percentage of cells treated with ATRA was higher in the 
G0/G1 period, lower in the sub-S period, and lower in the 
G2/M period when compared to the controls. Apoptotic 
cells were respectively 8.23 ± 1.28, 26.52 ± 1.67 and 
39.79 ± 3.96%, in the 10-7, 10-6 and 10-5 mol/L ATRA 
groups (Table 2). These results suggest that one of the 
mechanisms of the growth inhibitory effect of ATRA on 
LoVo cells is through an arrest in the G0/G1 phase of the 
cell cycle and apoptosis induction. 
 
 
Inhibition of VEGF protein expression in LoVo cells 
cultural supernatant by ATRA 
 
To determine whether ATRA had effect on the expression 
of VEGF protein in LoVo cells, VEGF expression level 
was detected by ELISA. There was no significant 
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2.5 5 10 15 20 
VEGF165 + 0 ATRA 105.23 106. 30 108.23 109.85 112.19 
VEGF165 + 10-7 ATRA 89.74* 91.24* 90.89* 97.56* 100.4* 
VEGF165 + 10-6 ATRA 75.43* 84.57* 85.67* 89.49* 95.62* 
VEGF165 + 10-5 ATRA 67.25* 70.63* 73.49 * 80.56* 86.53* 
 








Cell cycle (%) Apoptosis rate 
(%) G0/G1 S G2/M 
0 60.10±1.27 24.35±1.73 15.55±1.12 0 
10-7 75.69±1.81* 20.83±1.31 3.48±0.50 8.23±1.28* 
10-6 85.88±1.51* 6.89±1.12 6.13±0.40 26.52±1.67* 
10-5 84.80±1.40* 12.14±1.30 3.06±1.00 39.79±3.96* 
 




Table 3. VEGF level in LoVo cells cultural supernatant. 
 
ATRA (mol/L) VEGF level in LoVo cells cultural supernatant (pmol/ml, x ± s) 
24 h 48 h 72 h 
0 139.6925 ± 3.97 143.345 ± 6.46 145.7948 ± 3.65 
10-7 134.1528 ± 2.13b 110.1325 ± 1.97ab 88.1725 ± 3.62ab 
10-6 113.765 ± 2.21ab 92.27 ± 4.38ab 75.5075 ± 4.78ab 
10-5 99.0675 ± 5.16ab 62.32 ± 2.90ab 54.3675 ± 5.41ab 
 






Figure 2. Western blotting analysis of the expressions of 
VEGF. Lane 1,control; Lane 2,10-7 mol/L ATRA; Lane 3, 10-




group at 24 h (P = 0.1002) but with increase of the 
concentration of all-trans retinoic acid and prolonging of 
time, the ATRA groups had statistical prominence 
compared to the control group (P<0.05). As shown in 
Table 3, these results indicate that ATRA inhibited VEGF 
protein expression of LoVo cells in time-dependent and 
dose-dependent inhibitory fashions. 
Result of Western blotting 
 
Protein bands were photographed and quantified by 
densitometry in Western blot analysis. ATRA decreased 
the expression of VEGF protein in a dose-dependent 
manner, as shown in Figure 2. The actin protein was 
used as an internal control for normalization of protein 
loading. Right panel, relative levels of mRNA expression 
normalized to actin as determined by densitometry using 
UVI image analysis software. This experiment is 
representative of three separate determinations.  
 
 
The effect of ATRA on expression of VEGF receptors 
in LoVo cells by FCM 
 
To determine whether ATRA played a rule in expression 
of VEGF receptors in LoVo cells, we assessed the VEGF 
receptors of the LoVo cells before and after treatment 
with ATRA, using FCM. As shown in Figure 3, expression 
of VEGFR-1 and VEGFR-2  was  confirmed  in  LoVo  cell  







Figure 3. The effect of ATRA on expression of VEGF receptors in LoVo cells by FCM. (A) ATRA could reduce the expression of 
VEGF receptors in LoVo cells in time-dependent inhibitory fashions; (B) ATRA could reduce the expression of VEGF receptors in 
LoVo cells in dose-dependent inhibitory fashions; (C) the percentages of VEGFR-3 and isotype IgG-1 for 48 h. 
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lines. The percentages of VEGFR-3 and isotype IgG-1 for 
48 h were 2 ± 0.2 and 1.62 ± 0.8% (P = 0.5003). It meant 
that LoVo cells had no expression of VEGFR-3. These 
findings suggested that ATRA could reduce the 
expression of VEGF receptors in LoVo cells in time-





Colorectal cancer (CRC) is one of the most common 
malignancies in the world (Mehmet and Turkan, 2009). 
Approximately 50% of patients who undergo potentially 
curative surgery alone ultimately relapse and die of 
metastatic disease (Manfredi et al., 2006). The 
dependence of tumour growth and metastasis on blood 
vessels makes angiogenesis one of the fundamental 
hallmarks of cancer (Hanahan and Weinberg, 2000) and 
a rational target for (Carmeliet and Jain, 2000) several 
growth factor receptor pathways that have been 
implicated in the promotion of tumour angiogenesis. One 
of the major pathways involved in this process is the 
VEGF family of proteins, also known as vascular 
permeability factors, and its receptors. The VEGF 
pathway plays a crucial role in normal and pathologic 
angiogenesis, triggering multiple signalling networks that 
result in endothelial cell survival, migration, mitogenesis, 
differentiation, and vascular permeability (Ferrara and 
Davis-Smyth, 1997). Finding a way to inhibit the 
expression of VEGF and its receptors has been of great 
interest. 
ATRA is a derivative of vitamin A, and has attracted 
researchers due to the favorable effects of this agent in 
the treatment of acute promyelocytic leukemia. In 
additional studies, ATRA was found to inhibit cell growth 
(Xiao et  al.,  2006),  induce  differentiation  and  enhance  




apoptosis (Xu and Gong, 2004; Mirza et al., 2006; Huss 
et al., 2004) in a variety of malignant solid tumors through 
its influence on the expression of certain genes closely 
related to inhibition of tumor invasion and meta-
stasis(García-Alonso et al., 2005; Day et al., 2006; 
Suzuki et al., 2006).  
In our study of the effect of ATRA on growth and 
proliferation of LoVo cells, the MTT assay showed that 
ATRA inhibited the growth of LoVo cells in a dose-
dependent manner. Flow cytometry assays showed that 
the percentage of the cells treated with ATRA were higher 
in the G0/G1 and lower in the G2/M period when 
compared to the controls. These results show that ATRA 
inhibited the viability of LoVo cells and arrested the cells 
in G1 phase, blocked or delayed their entry into S phase, 
disturbed DNA synthesis, and induced apoptosis in the 
G1 phase. The results of ELISA show that there was no 
significant difference between 10-7 ATRA group and the 
control group at 24 h (P > 0.05) but with increasing 
concentration of all-trans retinoic acid and prolonged  
time of exposure, the ATRA groups had statistical 
prominence compared to the control group (P<0.05). 
These results indicate that ATRA inhibits VEGF protein 
expression of LoVo cells in time-dependent and dose-
dependent inhibitory fashions. In Western blot analysis, 
ATRA decreased the expression of VEGF protein in a 
dose-dependent manner,  
All types of specific receptors for VEGF, VEGFR-1, 
VEGFR-2 and VEGFR-3, are commonly distributed in 
endothelial cells. VEGFR-1 and VEGFR-2 are expressed 
predominantly on endothelial cells, but a few additional 
types of cells express one or both of these receptors 
(Ferrara, 2004; Ferrara et al., 2003). VEGFR-3 is initially 
expressed throughout the embryonic vasculature and is 
limited to lymphatic endothelial cells in later stages of 
development (Veikkola et al., 2001). VEGFRs belong to 
the receptor tyrosine kinase (RTK) family and have a 
characteristic structure with 7 Ig-like domains in the 
extracellular domain and a cytoplasmic tyrosine kinase 
domain with a long kinase insert region (Ferrara, 2004; 
Gu et al., 2003; Shibuya, 2002). VEGF acts by binding to 
the receptors and prompting endothelial cells 
proliferation. VEGF and its receptors are the most 
important pathways in tumor angiogenesis. Inhibition of 
VEGF/VEGFR pathways may suppress angiogenesis 
and tumour growth. However, the expression of VEGFR 
is not endothelial cells-specific, and recent emerging 
evidence has shown that VEGFRs are expressed in 
several types of non-endothelial cells, especially in 
tumour cells, which indicates that there is an autocrine 
pathway of VEGF in tumor cells (Jackson et al., 2002; 
Zhang et al., 2002; Dias et al., 2001). VEGFR may play 
an important role in paracrine and autocrine pathways of 
VEGF, and VEGFR inhibitors can inhibit tumor angio-
genesis and growth (Ciardiello et al., 2004).  
In the study, we examined further, the effect of ATRA 
on   VEGFR   expression   and   intended  to  confirm  the  
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anticancer activity of ATRA, which may block the 
paracrine and autocrine VEGF/VEGFR pathways thereby 
delaying new tumour blood vessel formation and tumour 
cell growth. Our results show that VEGFR-1(Flt-1) and 
VEGFR-2(KDR) except VEGFR-3 were expressed in the 
LoVo cells and their expression in tumour cell control 
were higher than that in ATRA-treated group. The 
percentage of VEGFR-1(Flt-1) and VEGFR-2(KDR) in 
tumor cells were significantly reduced in the ATRA-
treated groups (P < 0.05). The percentage of VEGFR-
1(Flt-1) and VEGFR-2(KDR) in the 10-5 mol/L group were 
less than those in the in the 10-7mol/L group (P < 0.05). 
These results suggest that ATRA can result in significant 
down-regulation of VEGFR-1(Flt-1) and VEGFR-2(KDR) 
in a dose-dependent manner. We showed the absence of 
VEGFR-3 expression in colorectal tumor LoVo cell lines. 
VEGFR-3 does play an important role in colon cancer 
proliferation and metastasis, but this is likely due to its 
presence on endothelial cells within the tumour (Bruns et 
al., 2000), rather than on the tumour cells themselves. 
The results of further experiments in vitro showed that 
exogenous VEGF165 could stimulate the growth of LoVo 
cells, and ATRA may have disturbed the stimulatory 
effect of VEGF165. It indicates that the autocrine or 
paracrine pathway of VEGF through VEGFRs is possible 
in colon carcinoma, and ATRA inhibits expression of Flt-1 
and KDR in endothelial and tumor cells. ATRA may block 
new blood vessel formation through the paracrine 
pathway and affect growth of tumor cells through the 






The results of our study showed that ATRA delayed 
growth of LoVo cells, inhibited their proliferation and 
induced apoptosis, which resulted in down-regulation of 
VEGFR-1(Flt-1) and VEGFR-2(KDR) expression in a 
dose-dependent manner. ATRA may block new blood 
vessel formation through the paracrine pathway and 
affect growth of tumor cells through the autocrine 
pathway of VEGF/VEGFRs in colorectal carcinoma, 
which if confirmed by further experiments, would provide 
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